The Effect of the Care Bundle to be Applied to Obesity Surgery Patients on Surgical Site Infection and Patient Comfort

NCT ID: NCT05930639

Last Updated: 2023-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-12

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of the most effective treatment methods of obesity is surgery. Bariatric surgery is classified as a clean-contaminated wound. The expected benefit from surgery is weight loss. However, surgical site infection is among the complications. Although many methods are applied to reduce these rates, it is not very possible to reduce them to zero. It is predicted that the incidence of infection will decrease with surgical care packages created from the combination of evidence-based interventions applied.

This study was a randomized controlled trial designed to determine the effect of the Surgical Site Infection (SSI) prevention package on SSI and patient comfort in patients undergoing bariatric surgery.

The questions to be answered by the research are;

* What is the effect of the care package applied to patients undergoing bariatric surgery on surgical site infection?
* What is the effect of the care package applied to patients undergoing bariatric surgery on comfort? .Patients aged 18 and over who have had bariatric surgery (sleeve gastrectomy) will be taken from a private hospital in Kayseri. All surgeries will be performed by the same surgeon. The care package (identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education) prepared for the experimental group will be applied. On the 30th day, the patient is called by phone and the surgical site infection findings are questioned.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Surgical Site Infection (SSI) was identified by the Center for Disease Control and Prevention (CDC) as a secondary surgical infection within 30 days after surgery. 2017 Health Service Related Infections Surveillance Network report in Turkey, according to the overall SSI rate is 0.72. A study in the literature found the incidence of as 22.2% after abdominal surgery. SSI has been shown to affect one in about every five patients undergoing abdominal surgery and has an incidence of approximately 20%-25% ' associated with contamination. In a comprehensive study conducted in Turkey, it was determined that SSI was seen in the third row after upper gastrointestinal (GIS) surgery and 47.06% of the patients were diagnosed with SSI after discharge.

In a retrospective study investigating the factors that predispose to SSI in general surgery; American Society of Anesthesiologists (ASA) score, wound classification (clean-contaminated, contaminated and dirty/infected wounds), operation history, prolongation of operation time, hypoalbuminemia, history of Chronic Obstructive Pulmonary Disease were defined as major risk factors for the development of SSI. Preoperative low hemoglobin, history of congestive heart failure, excessive alcohol use, surgery at the previous incision site, presence of existing infection, long preoperative and postoperative hospital stay, obesity, steroid use, preoperative epilation, operative data (surgeon's experience, incision device) , drain use, prosthetic mesh use, intraoperative blood transfusion) are other risk factors that increase the risk of SSI.It is suggested that by determining risk factors to reduce the incidence of SSI, it reduces hospital stay and health spending and decreases morbidity and mortality rates.

Bariatric surgery is an effective and widely used treatment for obese patients. The expected benefit from this surgical treatment is weight loss. In addition, this surgery can lead to the development of complications that have significant effects on morbidity and mortality.The use of antimicrobial prophylaxis for organisms causing SSI is important in bariatric surgery. The purpose of antibiotic prophylaxis is to reduce the bacterial load to a level that can be controlled by host defenses.

İnadvertent Perioperative Hypothermia (IPH) (body temperature below 36 °C) is a risk factor for the development of SSI. In a study investigating the effect of hypothermia on SSI in gastroenterological surgery, hypothermia was found to be associated with a higher incidence of organ/space SSI. IPH can cause prolonged hospital stay, cardiac morbidity, increased blood loss, and many complications such as tissue hypoxia and SSI due to neutrophil dysfunction.The CDC recommends maintaining perioperative normothermia to prevent SSI, and the recommendation is considered as the evidence level category IA. The current guidelines propose to use effective heating methods to maintain normothermia in the perioperative period and to measure the patient's body temperature.

Hyperglycemia is another independent risk factor for SSI. In a retrospective study, it was shown that serum glucose level higher than 110 mg/dL is associated with a gradual increase in post-surgical infection rates, and performing glycemic control in the first 48 hours after surgery reduces SSIs. CDC recommended performing perioperative glycemic control in patients with and without diabetes and use blood glucose target levels below 200 mg/dL.( Category IA - strong recommendation; high to medium quality evidence ). Hyperglycemia is a preventable variable to reduce the incidence of SSI.

Another important factor for SSI prevention is patient education. For this reason, the patient and his family should be trained to prevent proper wound care and SSI. However, the benefit of existing patient education materials is uncertain, and a limited number of patient training materials for SSI prevention were found for patients with bariatric surgery.

The concept of "Care Package" has been brought to the agenda by the American Institute for Healthcare Improvement (IHI) in order to achieve more optimal results by applying the interventions with positive results individually in line with evidence-based approaches. IHI has the criteria for inclusion of an element in the care package; It has identified it as consensus and high acceptance, providing solid evidence for clinical change, with little or no discussion of its activities. Maintenance packages with few and simple items have been determined to have better compliance rates. In a systematic review and meta-analysis study, it was reported that the use of SSI measure packages was estimated to prevent 60% of the incidence of SSI. SSI is a complex problem affected by many factors. SSI reduction strategies are multimodal and take place in a number of environments under the supervision of a large number of providers. Ensuring a high level of compliance with these risk reduction strategies is crucial to the success of SSI mitigation efforts.

In different studies, in which multidisciplinary care packages aimed at preventing SSI were applied, significant reductions were achieved in the long term and the use and development of care packages was recommended. Packages can improve the quality of surgical care for patients by providing a harmonious environment and standardization, effectively reducing the risk of SSI. This improvement in the quality of care may increase the comfort level of patients.The concept of comfort in the nursing discipline is based on meeting the needs and is accepted as a part of quality care.

This study is planned to determine the effect of the SSI prevention package on SSI and patient comfort in patients undergoing bariatric surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bariatric Surgery Candidate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Surgical Site Infection (SSI) prevention package; Antibiotic prophylaxis

determined antibiotic (active ingredient: imipenem cilastatin sodium)

Group Type EXPERIMENTAL

Surgical Site Infection (SSI) prevention package

Intervention Type OTHER

Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.

Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.

Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.

In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.

Before the operation and before discharge, the patient is educated about infection prevention measures.

Surgical Site Infection (SSI) prevention package;achieving and maintaining normothermia

Body temperature will be recorded with an infrared thermometer. The patient will be warmed with various passive heating techniques before and after the operation. To prevent hypothermia, the operating room ambient temperature will be kept in the range of 23-26°C.

Group Type EXPERIMENTAL

Surgical Site Infection (SSI) prevention package

Intervention Type OTHER

Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.

Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.

Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.

In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.

Before the operation and before discharge, the patient is educated about infection prevention measures.

Surgical Site Infection (SSI) prevention package; maintenance of normoglycemia

In the 2017 guidelines, perioperative glycemic control with a blood glucose level of \<200 mg/dL is recommended for patients with and without DM. Ideal blood glucose control should provide good glycemic control with a minimal incidence of hypoglycemia.

Group Type EXPERIMENTAL

Surgical Site Infection (SSI) prevention package

Intervention Type OTHER

Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.

Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.

Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.

In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.

Before the operation and before discharge, the patient is educated about infection prevention measures.

Surgical Site Infection (SSI) prevention package;patient education

SSI definition, SSI signs and symptoms, Hand hygiene, smoking, hair removal in the operation area, shower and bath before surgery. Conditions that require hospitalization, factors affecting wound healing, wound care, control time and who should be contacted will be discussed.

Group Type EXPERIMENTAL

Surgical Site Infection (SSI) prevention package

Intervention Type OTHER

Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.

Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.

Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.

In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.

Before the operation and before discharge, the patient is educated about infection prevention measures.

Surgical Site Infection (SSI) prevention package; Identification of risk factors

Risk factors of the individual created in line with the literature; Advanced age, history of skin or soft tissue infection, DM, alcohol addiction, smoking, preoperative albumin \<3.5 mg/dl, total bilirubin\>1.0 mg/dl, immunosuppression, long postoperative stay, long preoperative stay, high BMI,ASA score \> II,preoperative low Hgb level.

Risk factors associated with the surgical procedure; Presence of drain, prolongation of surgery time, preoperative skin preparation, blood transfusion, non-sterile equipment, insufficient ventilation, heavy operating room traffic, insufficient hemostasis.

Participants will be evaluated in terms of these risks.

Group Type EXPERIMENTAL

Surgical Site Infection (SSI) prevention package

Intervention Type OTHER

Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.

Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.

Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.

In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.

Before the operation and before discharge, the patient is educated about infection prevention measures.

control group

Antibiotic prophylaxis is applied to both groups. In the clinic where the study will be conducted, the blood glucose level of patients with a diagnosis of DM is controlled (5 measurements per day). All patients are fasted after 21.00 in the evening. The blood glucose levels of patients without a diagnosis of DM are not routinely checked. The body temperature of the patients is not monitored intraoperatively. No extra intervention is applied to maintain normothermia in the clinic and operating room.

There is no training on prevention of infection. There is no intervention in the control group.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Surgical Site Infection (SSI) prevention package

Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.

Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.

Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.

In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.

Before the operation and before discharge, the patient is educated about infection prevention measures.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

care bundle care package

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and over
* undergoing sleeve gastrectomy surgery
* who volunteered to participate in the study

Exclusion Criteria

* under 18 years old
* Surgeries other than sleeve gastrectomy
* not willing to participate in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Malatya Turgut Ozal University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hatice ÇAKIR

Research Assistant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Meryem YILMAZ

Role: STUDY_DIRECTOR

SİVAS CUMHURİYET UNIVERSITY

Hatice ÇAKIR

Role: PRINCIPAL_INVESTIGATOR

Malatya Turgut Ozal University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hatice ÇAKIR

Malatya, , Turkey (Türkiye)

Site Status RECRUITING

Meryem Yilmaz

Sivas, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

research assistant

Role: CONTACT

+90 05534491539

professor

Role: CONTACT

+90 05310102028

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hatice ÇAKIR (RESEARCH ASSISTANT)

Role: primary

+90 05534491539

MERYEM YILMAZ (PROFESSOR)

Role: primary

+90 0531 010 2028

References

Explore related publications, articles, or registry entries linked to this study.

Aga E, Keinan-Boker L, Eithan A, Mais T, Rabinovich A, Nassar F. Surgical site infections after abdominal surgery: incidence and risk factors. A prospective cohort study. Infect Dis (Lond). 2015;47(11):761-7. doi: 10.3109/23744235.2015.1055587. Epub 2015 Jun 26.

Reference Type BACKGROUND
PMID: 26114986 (View on PubMed)

Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008 Jun;36(5):309-32. doi: 10.1016/j.ajic.2008.03.002. No abstract available.

Reference Type BACKGROUND
PMID: 18538699 (View on PubMed)

Isik O, Kaya E, Dundar HZ, Sarkut P. Surgical Site Infection: Re-assessment of the Risk Factors. Chirurgia (Bucur). 2015 Sep-Oct;110(5):457-61.

Reference Type BACKGROUND
PMID: 26531790 (View on PubMed)

Haridas M, Malangoni MA. Predictive factors for surgical site infection in general surgery. Surgery. 2008 Oct;144(4):496-501; discussion 501-3. doi: 10.1016/j.surg.2008.06.001.

Reference Type BACKGROUND
PMID: 18847631 (View on PubMed)

Alkaaki A, Al-Radi OO, Khoja A, Alnawawi A, Alnawawi A, Maghrabi A, Altaf A, Aljiffry M. Surgical site infection following abdominal surgery: a prospective cohort study. Can J Surg. 2019 Apr 1;62(2):111-117. doi: 10.1503/cjs.004818.

Reference Type BACKGROUND
PMID: 30907567 (View on PubMed)

Carvalho RLR, Campos CC, Franco LMC, Rocha AM, Ercole FF. Incidence and risk factors for surgical site infection in general surgeries. Rev Lat Am Enfermagem. 2017 Dec 4;25:e2848. doi: 10.1590/1518-8345.1502.2848.

Reference Type BACKGROUND
PMID: 29211190 (View on PubMed)

Wang Z, Chen J, Wang P, Jie Z, Jin W, Wang G, Li J, Ren J. Surgical Site Infection After Gastrointestinal Surgery in China: A Multicenter Prospective Study. J Surg Res. 2019 Aug;240:206-218. doi: 10.1016/j.jss.2019.03.017. Epub 2019 Apr 12.

Reference Type BACKGROUND
PMID: 30986636 (View on PubMed)

Chopra T, Zhao JJ, Alangaden G, Wood MH, Kaye KS. Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens. Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):317-28. doi: 10.1586/erp.10.26.

Reference Type BACKGROUND
PMID: 20545596 (View on PubMed)

Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, Reinke CE, Morgan S, Solomkin JS, Mazuski JE, Dellinger EP, Itani KMF, Berbari EF, Segreti J, Parvizi J, Blanchard J, Allen G, Kluytmans JAJW, Donlan R, Schecter WP; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017 Aug 1;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.

Reference Type BACKGROUND
PMID: 28467526 (View on PubMed)

Tsuchida T, Takesue Y, Ichiki K, Uede T, Nakajima K, Ikeuchi H, Uchino M. Influence of Peri-Operative Hypothermia on Surgical Site Infection in Prolonged Gastroenterological Surgery. Surg Infect (Larchmt). 2016 Oct;17(5):570-6. doi: 10.1089/sur.2015.182. Epub 2016 Mar 30.

Reference Type BACKGROUND
PMID: 27027205 (View on PubMed)

Zellmer C, Zimdars P, Parker S, Safdar N. Evaluating the usefulness of patient education materials on surgical site infection: a systematic assessment. Am J Infect Control. 2015 Feb;43(2):167-8. doi: 10.1016/j.ajic.2014.10.020. Epub 2014 Dec 23.

Reference Type BACKGROUND
PMID: 25541334 (View on PubMed)

Ban KA, Minei JP, Laronga C, Harbrecht BG, Jensen EH, Fry DE, Itani KM, Dellinger EP, Ko CY, Duane TM. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg. 2017 Jan;224(1):59-74. doi: 10.1016/j.jamcollsurg.2016.10.029. Epub 2016 Nov 30. No abstract available.

Reference Type BACKGROUND
PMID: 27915053 (View on PubMed)

Weiser MR, Gonen M, Usiak S, Pottinger T, Samedy P, Patel D, Seo S, Smith JJ, Guillem JG, Temple L, Nash GM, Paty PB, Baldwin-Medsker A, Cheavers CE, Eagan J, Garcia-Aguilar J; Memorial Sloan Kettering Multidisciplinary Surgical-Site Infection Reduction Team. Effectiveness of a multidisciplinary patient care bundle for reducing surgical-site infections. Br J Surg. 2018 Nov;105(12):1680-1687. doi: 10.1002/bjs.10896. Epub 2018 Jul 4.

Reference Type BACKGROUND
PMID: 29974946 (View on PubMed)

Cakir H, Yilmaz M. Impact of a Care Bundle on Surgical Site Infections and Patient Comfort in Bariatric Surgery: A Randomized Prospective Study. Obes Surg. 2025 Sep;35(9):3810-3821. doi: 10.1007/s11695-025-08116-9. Epub 2025 Aug 23.

Reference Type DERIVED
PMID: 40848119 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-07-22/30

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bariatric Surgery for Obesity
NCT06901440 NOT_YET_RECRUITING
8-Year Outcomes After Sleeve Gastrectomy
NCT07348822 ACTIVE_NOT_RECRUITING
Opioid-Free Versus Opioid-Based Anesthesia in Bariatric
NCT07105839 NOT_YET_RECRUITING PHASE4